Curriculum

• A phase 2a, double-blind, randomized, placebo-controlled, parallel group study to evaulate the efficacy and safety of oral pf-06651600 and pf-06700841 as induction and open label extension treatment in subjects with moderate to severe Crohn’s disease – b7981007
• A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of bms-986165 in subjects with moderate to severe Crohn's disease
• A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of bms-986165 in subjects with moderate to severe ulcerative colitis.
• Induction study #1 - a phase 3, multicenter, randomized, double-blind, placebo-controlled study of oral Ozanimod as induction therapy for moderately to severely active Crohn’s disease.
• A phase 3b, multicenter, randomized, blinded, active-controlled study to compare the efficacy and safety of ustekinumab to that of adalimumab in the treatment of biologic naïve subjects with moderately-to-severely active Crohn’s disease. Seavue: safety and efficacy of adalimumab versus ustekinumab for one year.
• A phase 2b, double-blind, randomized, placebo-controlled, parallel group, dose ranging study of oral pf-06651600 and pf-06700841 as induction and chronic therapy in subjects with moderate to severe ulcerative colitis
• A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of bms-986165 in subjects with moderate to severe Crohn's disease
• A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of bms-986165 in subjects with moderate to severe ulcerative colitis.
• Induction study #1 - a phase 3, multicenter, randomized, double-blind, placebo-controlled study of oral Ozanimod as induction therapy for moderately to severely active Crohn’s disease.
• A phase 3b, multicenter, randomized, blinded, active-controlled study to compare the efficacy and safety of ustekinumab to that of adalimumab in the treatment of biologic naïve subjects with moderately-to-severely active crohn’s disease. Seavue: safety and efficacy of adalimumab versus ustekinumab for one year.
• A phase 2b, double-blind, randomized, placebo-controlled, parallel group, dose ranging study of oral pf-06651600 and pf-06700841 as induction and chronic therapy in subjects with moderate to severe ulcerative colitis

• Prodotti delle ricerche:
• Goessens L, Colombel JF, Outtier A,  Ferrante M, Sabino J, Judge C,  Saeidi R, Rabbitt L, Armuzzi A, Domenech E, Michalopoulos G, Cremer A, García-Alonso FJ, Molnar T, Karmiris K,  Gecse K,  Oostrom J, Löwenberg M, Farkas K, Atreya R, Ribaldone DG, Selinger C, Hoentjen F, Bihin B, Sebastian S, European COMBIO study group and Jean-François Rahier. Safety and efficacy of combining two biological therapies together or a biological therapy with a new small molecule in patients with inflammatory bowel disease and other immune mediated disease. United European Gastroenterol J. Accepted manuscript

• Prodotti delle ricerche:

• R. Goll, J. Kay-Martin, A. Viola, E. Paulssen, Ø.K. Moe, G. Cui, W. Fries, J. Florholmen. TNF gene activation used as criterion to discontinue biologic therapy – A patient series introducing the NovaPrime TNF kit. J Crohns Colitis, Volume 15, Issue Supplement_1, May 2021.

• Prodotti delle ricerche:

• Viola A, Muscianisi M, Macaluso FS, Ventimiglia M, Cappello M, Privitera AC, Magnano A, Pluchino D, Magrì G, Ferracane C, Mocciaro F, Garufi S, Giuffrida E, Costantino G, Fiocco G, Grova M, Guida L, Alibrandi A, Orlando A, Fries W; “Sicilian Network for Inflammatory Bowel Disease (SN‐IBD)”. Ustekinumab in Crohn's disease: Real-world outcomes from the Sicilian network for inflammatory bowel diseases. JGH Open. 2021 Feb 2; 5(3):364-370.
• Macaluso FS, Fries W, Viola A, Costantino G, Muscianisi M, Cappello M, Guida L, Giuffrida E, Magnano A, Pluchino D, Ferracane C, Magrì G, Di Mitri R, Mocciaro F, Privitera AC, Camilleri S, Garufi S, Renna S, Casà A, Scrivo B, Ventimiglia M, Orlando A. Effectiveness of Ustekinumab on Crohn's Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). Expert Opin Biol Ther. 2020 Nov; 20(11):1381-1384.
• Macaluso FS, Fries W, Renna S, Viola A, Muscianisi M, Cappello M, Guida L, Siringo S, Camilleri S, Garufi S, Privitera AC, Belluardo N, Giangreco E, Bertolami C, Vassallo R, Rizzuto G, Orlando R, Ventimiglia M, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study. United European Gastroenterol J. 2020 Nov; 8(9):1045-1055
• Macaluso FS, Ventimiglia M, Fries W, Viola A, Cappello M, Scrivo B, Magnano A, Pluchino D, Camilleri S, Garufi S, Mitri RD, Mocciaro F, Magrì G, Ferracane C, Citrano M, Graziano F, Bertolami C, Renna S, Orlando R, Rizzuto G, Cottone M, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD).. A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis. Dig Liver Dis. 2020 Dec; 52(12):1461-1466.
• Macaluso FS, Ventimiglia M, Fries W, Viola A, Sitibondo A, Cappello M, Scrivo B, Busacca A, Privitera AC, Camilleri S, Garufi S, Di Mitri R, Mocciaro F, Belluardo N, Giangreco E, Bertolami C, Renna S, Orlando R, Rizzuto G, Cottone M, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease. J Gastroenterol Hepatol. 2021 Jan; 36(1):105-111.
• Macaluso FS, Fries W, Viola A, Centritto A, Cappello M, Giuffrida E, Privitera AC, Piccillo G, Magnano A, Vinci E, Vassallo R, Trovatello A, Belluardo N, Giangreco E, Camilleri S, Garufi S, Bertolami C, Ventimiglia M, Renna S, Orlando R, Rizzuto G, Orlando A. The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches. Inflamm Bowel Dis. 2021 Jan 19;27(2):182-189
• Porcari S, Viola A, Orlando A, Privitera AC, Ferracane C, Cappello M, Vitello A, Siringo S, Inserra G, Magnano A, Mocciaro F, Di Mitri R, Belluardo N, Fidanza O, Garufi S, Magrì G, Bertolami C, Carroccio A, Macaluso FS, Renna S, Ventimiglia M, Alibrandi A, Cottone M, Fries W; Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). Drugs Aging. 2020 May;37(5):383-392.

• Prodotti delle ricerche:

• Pugliese D, Privitera G, Rogai F, Variola A, Viola A, Laterza L, Privitera AC, Allocca M, Bossa F, Cappello M, Daperno M, Lorenzon G, Mazzuoli S, Principi M, Sablich R, Moser L, Ferronato A, Traini S, Tapete G, Bodini G, Di Girolamo M, Grossi L, Mocci G, Ricci C, Saibeni S, Festa S, Spagnuolo R, Cortelezzi CC, Mocciaro F, Rizzello F, Armuzzi A; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study. United European Gastroenterol J. 2021 Feb; 9(1):102-109.
• Saibeni S, Scucchi L, Dragoni G, Bezzio C, Miranda A, Ribaldone DG, Bertani A, Bossa F, Allocca M, Buda A, Mocci G, Soriano A, Mazzuoli S, Bertani L, Baccini F, Loddo E, Privitera AC, Sartini A, Viscido A, Grossi L, Casini V, Gerardi V, Ascolani M, Ruscio MD, Casella G, Savarino E, Stradella D, Pumpo R, Cortelezzi CC, Daperno M, Ciardo V, Nardone OM, Caprioli F, Vitale G, Cappello M, Comberlato M, Alvisi P, Festa S, Campigotto M, Bodini G, Balestrieri P, Viola A, Pugliese D, Armuzzi A, Fantini MC, Fiorino G; IG-IBD (Italian Group for the study of Inflammatory Bowel Disease). Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care. United European Gastroenterol J. 2020 Dec; 8(10):1228-1235.
• Viola A, Monterubbianesi R, Scalisi G, Furfaro F, Rea M, Saibeni S, Aratari A, Bringiotti R, Casella G, Cantoro L, Frankovic I, Calella F, Pugliese D, Orlando S, Samperi L, Cappello M, Mocci G, Manetti N, Annese V, Privitera AC, Inserra G, Caprioli F, D'Incà R, Principi M, Papi C, Castiglione F, Danese S, Ardizzone S, Bossa F, Kohn A, Manguso F, Alibrandi A, Fiorino G, Armuzzi A, Fries W; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease 'AGED' study. Eur J Gastroenterol Hepatol. 2019 Nov;31(11):1361-1369.
• Biancone L, Armuzzi A, Scribano ML, Castiglione F, D'Incà R, Orlando A, Papi C, Daperno M, Vecchi M, Riegler G, Fries W, Alvisi P, Meucci G, Mocciaro F, Rogai F, Festa S, Guidi L, Testa A, Spina L, Renna S, Viola A, Patturelli M, Di Mitri R, Frankovic I, Calabrese E, Petruzziello C, De Cristofaro E, Sena G, Ruffa A, Neri B, Rossi A. Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study. Inflamm Bowel Dis. 2020 Feb 11;26(3):450-459.
• Favale A, Onali S, Caprioli F, Pugliese D, Armuzzi A, Macaluso FS, Orlando A, Viola A, Fries W, Rispo A, Castiglione F, Mocci G, Chicco F, Usai P, Calabrese E, Biancone L, Monteleone G, Fantini MC; Italian Group for the study of Inflammatory Bowel Disease (IG-IBD).Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab. Inflamm Bowel Dis. 2019 Oct 18;25(11):1805-1812.
• W. Fries, A. Viola , N. Manetti, I. Frankovic , D. Pugliese, R.Monterubbianesi, G. Scalisi, A. Aratari, L. Cantoro, M. Cappello, L. Samperi , S. Saibeni , G. Casella, G. Mocci, M. Rea, F. Furfaro, A. Contaldo, A. Magarotto, F. Calella, F. Manguso, G. Inserra, A. C. Privitera, M. Principi , F. Castiglione, F. Caprioli, S. Ardizzone , S. Danese, C. Papi, F. Bossa, A. Kohn, A. Armuzzi, R. D’Incà, V. Annese, A. Alibrandi, S. Bonovas, G. Fiorino. Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD “AGED study”. Dig Liver Dis. 2017 Jan;49(1):17-23.
• Vitello A, Grova M, Pugliese D, Rizzello F, Lanzarotto F, Lavagna A, Caccaro R, Cappello M, Viola A, Ribaldone DG, Principi M, Stasi E, Scribano ML, Maida M, Soriano A, Bezzio C, Bodini G, Mocciaro F, Privitera AC, Simondi D, Giuffrida E, D'Incà R, Ricci C, Gionchetti P, Armuzzi A, Orlando A, Daperno M; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy. Dig Liver Dis. 2021 Sep 16:S1590-8658(21)00761-1. doi: 10.1016/j.dld.2021.08.020. Epub ahead of print.

• Prodotti della ricerca

• Viola A, Muscianisi M, Macaluso FS, Ventimiglia M, Cappello M, Privitera AC, Magnano A, Pluchino D, Magrì G, Ferracane C, Mocciaro F, Garufi S, Giuffrida E, Costantino G, Fiocco G, Grova M, Guida L, Alibrandi A, Orlando A, Fries W; “Sicilian Network for Inflammatory Bowel Disease (SN‐IBD)”. Ustekinumab in Crohn's disease: Real-world outcomes from the Sicilian network for inflammatory bowel diseases. JGH Open. 2021 Feb 2; 5(3):364-370.

• Titolo del progetto: Assessment of Vedolizumab and Ustekinumab in the Elderly (Studio AVENUE).

• Citazioni totali n. 289
• Citazioni medie per pubblicazione n. 8.7
• h-index = 9
• IF complessivo (su 38 pubblicazioni):  156
• IF medio per pubblicazione: 4.1

1. W. Fries, A. Viola , N. Manetti, I. Frankovic , D. Pugliese, R.Monterubbianesi, G. Scalisi, A. Aratari, L. Cantoro, M. Cappello, L. Samperi , S. Saibeni , G. Casella, G. Mocci, M. Rea, F. Furfaro, A. Contaldo, A. Magarotto, F. Calella, F. Manguso, G. Inserra, A. C. Privitera, M. Principi , F. Castiglione, F. Caprioli, S. Ardizzone , S. Danese, C. Papi, F. Bossa, A. Kohn, A. Armuzzi, R. D’Incà, V. Annese, A. Alibrandi, S. Bonovas, G. Fiorino. Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD “AGED study”. Dig Liver Dis 2017; 49:17-23.  IF: 4
2. Viola A, Costantino G, Privitera AC, Bossa F, Lauria A, Grossi L, Principi MB, Della Valle N, Cappello M. Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study.  World J Gastrointest Pharmacol Ther. 2017; 8:131-136. IF: 0
3. Fiorino G, Manetti N, Armuzzi A, Orlando A, Variola A.,Bonovas S, Bossa F, Maconi G, D'Incà R, Lionetti P, Cantoro L.,Fries W., Annunziata M.L.l, Costa F.,Terpin M.M.,Biancone L.,Cortelezzi C.C.,Amato A.,Ardizzone S.,Danese S.,Guidi L.,Rizzuto G.,Massella A.,Andriulli A.,Massari A.,Lorenzon G.,Ghione S.,Kohn A.,Ventra A.,Annese V. Annese V.,Principi M.,Di Girolamo M.,Bertani A.,Saettone S.,Tari R.,Petruzzellis C.,Guglielmi F.W.,Mazzuoli S.,Cappello M.,Viola A.,Castiglione F.,Nardone O.,Di Sabatino A.,Saibeni S.,Bezzio C.,Caserta L.,Parodi M.C.,Meucci G.,Colli A.,Ronchetti A.,Vecchi M.l,Bertani L.,Bosani M.A.,Tronconi E.,Imperiali G.,Salerno R.,Rogai F.,Milani S.,Pugliese D.,Renna S.,Geccherle A.,Martino G.,Cassinotti A. The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. Inflamm Bowel Dis. 2017; 23:233–243. IF: 5.3
4. Viola A, Pugliese D, Renna S, Furfaro F, Caprioli F, D'Incà R, Bossa F, Mazza S, Costantino G, Fantini MC, Fiorino G, Alibrandi A, Orlando A, Armuzzi A, Fries W. Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study. Dig Liver Dis. 2019; 51:510-515. IF: 4
5. Viola A, Caltagirone AM, Campisi G, Guarneri G, Cappello M. Stevens-Johnson syndrome on treatment with sulfasalazine for Crohn's disease: Need for a multidisciplinary approach. Turk J Gastroenterol. 2019; 30:211-212. IF: 1.8
6. Favale A, Onali S, Caprioli F, Pugliese D, Armuzzi A, Macaluso FS, Orlando A, Viola A, Fries W, Rispo A, Castiglione F, Mocci G, Chicco F, Usai P, Calabrese E, Biancone L, Monteleone G, Fantini MC; Italian Group for the study of Inflammatory Bowel Disease (IG-IBD). Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab. Inflamm Bowel Dis. 2019; 25:1805-1812. IF: 5.3
7. Viola A, Fries W. Inflammatory Bowel Disease in the Elderly – Knowledge Gaps and Potential Directions in Research. Gastroenterology Medicine & Research. 2019; 3:1-3. IF: 0.9
8. Viola A, Monterubbianesi R, Scalisi G, Furfaro F, Rea M, Saibeni S, Aratari A, Bringiotti R, Casella G, Cantoro L, Frankovic I, Calella F, Pugliese D, Orlando S, Samperi L, Cappello M, Mocci G, Manetti N, Annese V, Privitera AC, Inserra G, Caprioli F, D'Incà R, Principi M, Papi C, Castiglione F, Danese S, Ardizzone S, Bossa F, Kohn A, Manguso F, Alibrandi A, Fiorino G, Armuzzi A, Fries W; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease 'AGED' study. Eur J Gastroenterol Hepatol. 2019 Nov;31(11):1361-1369. IF:2.5
9. Biancone L, Armuzzi A, Scribano ML, Castiglione F, D'Incà R, Orlando A, Papi C, Daperno M, Vecchi M, Riegler G, Fries W, Alvisi P, Meucci G, Mocciaro F, Rogai F, Festa S, Guidi L, Testa A, Spina L, Renna S, Viola A, Patturelli M, Di Mitri R, Frankovic I, Calabrese E, Petruzziello C, De Cristofaro E, Sena G, Ruffa A, Neri B, Rossi A. Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study. Inflamm Bowel Dis. 2020 Feb 11;26(3):450-459. IF: 5.3
10. Porcari S, Viola A, Orlando A, Privitera AC, Ferracane C, Cappello M, Vitello A, Siringo S, Inserra G, Magnano A, Mocciaro F, Di Mitri R, Belluardo N, Fidanza O, Garufi S, Magrì G, Bertolami C, Carroccio A, Macaluso FS, Renna S, Ventimiglia M, Alibrandi A, Cottone M, Fries W; Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). Drugs Aging. 2020 May;37(5):383-392. IF: 3.9
11. Privitera G, Onali S, Pugliese D, Renna S, Savarino E, Viola A, Ribaldone DG, Buda A, Bezzio C, Fiorino G, Fantini MC, Scaldaferri F, Guidi L, Danese S, Gasbarrini A, Orlando A, Armuzzi A. Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease. J Crohns Colitis. 2020 Jul 17:jjaa149. Epub ahead of print.  IF: 9.0
12. Viola A, Fontana A, Belvedere A, Scoglio R, Costantino G, Sitibondo A, Muscianisi M, Inferrera S, Bruno LM, Alibrandi A, Trifirò G, Fries W. Diagnostic accuracy of faecal calprotectin in a symptom-based algorithm for early diagnosis of inflammatory bowel disease adjusting for differential verification bias using a Bayesian approach. Scand J Gastroenterol. 2020 Oct; 55(10):1176-1184. IF: 2.4
13. Fantini MC, Biancone L, Dragoni G, Bezzio C, Miranda A, Ribaldone DG, Bertani A, Bossa F, Allocca M, Buda A, Mocci G, Soriano A, Guglielmi FW, Bertani L, Baccini F, Loddo E, Privitera AC, Sartini A, Viscido A, Grossi L, Casini V, Gerardi V, Ascolani M, Di Ruscio M, Casella G, Savarino E, Stradella D, Pumpo R, Cortelezzi CC, Daperno M, Ciardo V, Nardone OM, Caprioli F, Vitale G, Cappello M, Comberlato M, Alvisi P, Festa S, Campigotto M, Bodini G, Balestrieri P, Viola A, Pugliese D, Armuzzi A, Saibeni S, Fiorino G. Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey. Inflamm Bowel Dis. 2020 Oct 23;26(11): e134-e136. IF: 5.3
14. Macaluso FS, Fries W, Renna S, Viola A, Muscianisi M, Cappello M, Guida L, Siringo S, Camilleri S, Garufi S, Privitera AC, Belluardo N, Giangreco E, Bertolami C, Vassallo R, Rizzuto G, Orlando R, Ventimiglia M, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study. United European Gastroenterol J. 2020 Nov; 8(9):1045-1055. IF: 3.4
15. Viola A, Marino F, Atzeni F, Fries W. Extra-intestinal manifestations in inflammatory bowel disease. APMB - Atti della Accademia Peloritana dei Pericolanti Classe di Scienze Medico Biologiche. 2020; 108:1-11. IF: 0
16. Macaluso FS, Fries W, Viola A, Costantino G, Muscianisi M, Cappello M, Guida L, Giuffrida E, Magnano A, Pluchino D, Ferracane C, Magrì G, Di Mitri R, Mocciaro F, Privitera AC, Camilleri S, Garufi S, Renna S, Casà A, Scrivo B, Ventimiglia M, Orlando A. Effectiveness of Ustekinumab on Crohn's Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). Expert Opin Biol Ther. 2020; 20:1381-1384.  IF: 5.3
17. Macaluso FS, Ventimiglia M, Fries W, Viola A, Cappello M, Scrivo B, Magnano A, Pluchino D, Camilleri S, Garufi S, Mitri RD, Mocciaro F, Magrì G, Ferracane C, Citrano M, Graziano F, Bertolami C, Renna S, Orlando R, Rizzuto G, Cottone M, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis. Dig Liver Dis. 2020; 52:1461-1466. IF: 4
18. Viola A, Chiappetta MF, Scolaro M, Bignoli F, Versace A, Fries W. Direct oral anticoagulants increase the risk of anaemia and hospitalization in IBD patients with active intestinal disease. Dig Liver Dis. 2020; 52:1525-1526. IF: 4
19. Saibeni S, Scucchi L, Dragoni G, Bezzio C, Miranda A, Ribaldone DG, Bertani A, Bossa F, Allocca M, Buda A, Mocci G, Soriano A, Mazzuoli S, Bertani L, Baccini F, Loddo E, Privitera AC, Sartini A, Viscido A, Grossi L, Casini V, Gerardi V, Ascolani M, Ruscio MD, Casella G, Savarino E, Stradella D, Pumpo R, Cortelezzi CC, Daperno M, Ciardo V, Nardone OM, Caprioli F, Vitale G, Cappello M, Comberlato M, Alvisi P, Festa S, Campigotto M, Bodini G, Balestrieri P, Viola A, Pugliese D, Armuzzi A, Fantini MC, Fiorino G; IG-IBD (Italian Group for the study of Inflammatory Bowel Disease). Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care. United European Gastroenterol J. 2020; 8:1228-1235. IF: 3.4
20. Macaluso FS, Fries W, Viola A, Centritto A, Cappello M, Giuffrida E, Privitera AC, Piccillo G, Magnano A, Vinci E, Vassallo R, Trovatello A, Belluardo N, Giangreco E, Camilleri S, Garufi S, Bertolami C, Ventimiglia M, Renna S, Orlando R, Rizzuto G, Orlando A. The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches. Inflamm Bowel Dis. 2021; 27:182-189. IF: 5.3
21. Macaluso FS, Ventimiglia M, Fries W, Viola A, Sitibondo A, Cappello M, Scrivo B, Busacca A, Privitera AC, Camilleri S, Garufi S, Di Mitri R, Mocciaro F, Belluardo N, Giangreco E, Bertolami C, Renna S, Orlando R, Rizzuto G, Cottone M, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease. J Gastroenterol Hepatol. 2021; 36:105-111. IF: 4
22. Pugliese D, Privitera G, Rogai F, Variola A, Viola A, Laterza L, Privitera AC, Allocca M, Bossa F, Cappello M, Daperno M, Lorenzon G, Mazzuoli S, Principi M, Sablich R, Moser L, Ferronato A, Traini S, Tapete G, Bodini G, Di Girolamo M, Grossi L, Mocci G, Ricci C, Saibeni S, Festa S, Spagnuolo R, Cortelezzi CC, Mocciaro F, Rizzello F, Armuzzi A; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study. United European Gastroenterol J. 2021; 9:102-109. IF: 3.4
23. Viola A, Muscianisi M, Macaluso FS, Ventimiglia M, Cappello M, Privitera AC, Magnano A, Pluchino D, Magrì G, Ferracane C, Mocciaro F, Garufi S, Giuffrida E, Costantino G, Fiocco G, Grova M, Guida L, Alibrandi A, Orlando A, Fries W; “Sicilian Network for Inflammatory Bowel Disease (SN‐IBD)”. Ustekinumab in Crohn's disease: Real-world outcomes from the Sicilian network for inflammatory bowel diseases. JGH Open. 2021; 5:364-370. IF: 1.5
24. Calabrese E, Rispo A, Zorzi F, De Cristofaro E, Testa A, Costantino G, Viola A, Bezzio C, Ricci C, Prencipe S, Racchini C, Stefanelli G, Allocca M, Scotto di Santolo S, D'Auria MV, Balestrieri P, Ricchiuti A, Cappello M, Cavallaro F, Guarino AD, Maconi G, Spagnoli A, Monteleone G, Castiglione F. Ultrasonography Tight Control and Monitoring in Crohn's Disease During Different Biological Therapies: A Multicenter Study. Clin Gastroenterol Hepatol. 2021 Mar 26: S1542-3565(21)00340-2 (in press). IF: 11.3
25. Belvedere A, Scoglio R, Viola A, Costantino G, Sitibondo A, Muscianisi M, Inferrera S, Alibrandi A, Fries W. A real world investigation on prevalence, clinical features, and therapy of inflammatory bowel disease in the city of Messina, Italy. Acta Biomed. 2021; 92:e2021161. IF: 0.7
26. Viola A, Giambò F, Chiappetta MF, Costantino G, Pallio S, Fries W. Management of patients with inflammatory bowel disease and outcomes during the first wave of the Covid-19 pandemic. Dig Liver Dis. 2021; 53:689-690. IF: 4
27. Viola A, Fiorino G, Costantino G, Fries W. Epidemiology and clinical course of late onset inflammatory bowel disease. Minerva Gastroenterol (Torino). 2021. (in press). IF: 3.0
28. Macaluso FS, Cappello M, Busacca A, Fries W, Viola A, Costantino G, Magnano A, Vinci E, Ferracane C, Privitera AC, Piccillo G, Belluardo N, Giangreco E, Romano C, Citrano M, Graziano F, Garufi S, Bertolami C, Ventimiglia M, Scrivo B, Teresi G, Renna S, Rizzuto G, Casà A, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501. J Gastroenterol Hepatol. 2021 Jun 21. (in press) IF: 4.0
29. Vitello A, Grova M, Pugliese D, Rizzello F, Lanzarotto F, Lavagna A, Caccaro R, Cappello M, Viola A, Ribaldone DG, Principi M, Stasi E, Scribano ML, Maida M, Soriano A, Bezzio C, Bodini G, Mocciaro F, Privitera AC, Simondi D, Giuffrida E, D'Incà R, Ricci C, Gionchetti P, Armuzzi A, Orlando A, Daperno M; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy. Dig Liver Dis. 2021 Sep 16:S1590-8658(21)00761-1. doi: 10.1016/j.dld.2021.08.020. (in press) IF: 4
30. Chiappetta MF, Viola A, Mastronardi M, Turchini L, Carparelli S, Orlando A, Biscaglia G, Miranda A, Guida L, Costantino G, Scaldaferri F, Bossa F, Renna S, Cappello M, Alibrandi A, Orlando A, Armuzzi A, Fries W. One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy. Expert Opin Biol Ther. 2021. Epub ahead of print. IF: 4.3
31. Goessens L, Colombel JF, Outtier A,  Ferrante M, Sabino J, Judge C,  Saeidi R, Rabbitt L, Armuzzi A, Domenech E, Michalopoulos G, Cremer A, García-Alonso FJ, Molnar T, Karmiris K,  Gecse K,  Oostrom J, Löwenberg M, Farkas K, Atreya R, Ribaldone DG, Selinger C, Hoentjen F, Bihin B, Sebastian S, European COMBIO study group and Jean-François Rahier. Safety and efficacy of combining two biological therapies together or a biological therapy with a new small molecule in patients with inflammatory bowel disease and other immune mediated disease. United European Gastroenterol J. 2021, 9(10), 1136–1147. IF: 3.4
32. Rao S, Viola A, Ksissa O, Fries W. Ménétrier’s disease in a patient with refractory Ulcerative Colitis: a clinical challenge and review of the literature. BMJ Case Reports. Accepted manuscript. IF: 0
33. Viola A, Muscianisi M, Voti RL, Costantino G, Alibrandi A, Fries W. Predictors of Covid-19 vaccination acceptance in IBD patients: a prospective study. Eur J Gastroenterol Hepatol. 2021;33(1S Suppl 1):e1042-e1045. IF: 3.4
34. Neri B, Scribano ML, Armuzzi A, Castiglione F, D'Incà R, Orlando A, Festa S, Riegler G, Fries W, Meucci G, Alvisi P, Mocciaro F, Papi C, Mossa M, Sena G, Guidi L, Testa A, Renna S, Frankovic I, Viola A, Patturelli M, Chiaramonte C, Biancone L, On Behalf Of Ig-Ibd Italian Group For The Study Of Inflammatory Bowel Disease. Incident Colorectal Cancer in Inflammatory Bowel Disease. Cancers (Basel). 2022 Jan 30;14(3):721. IF:6.6
35. Calabrese E, Rispo A, Zorzi F, De Cristofaro E, Testa A, Costantino G, Viola A, Bezzio C, Ricci C, Prencipe S, Racchini C, Stefanelli G, Allocca M, Scotto di Santolo S, D'Auria MV, Balestrieri P, Ricchiuti A, Cappello M, Cavallaro F, Guarino AD, Maconi G, Spagnoli A, Monteleone G, Castiglione F. Ultrasonography Tight Control and Monitoring in Crohn's Disease During Different Biological Therapies: A Multicenter Study. Clin Gastroenterol Hepatol. 2022 Apr;20(4):e711-e722. IF: 11.3
36. Macaluso FS, Cappello M, Crispino F, Grova M, Privitera AC, Piccillo G, Magnano A, Ferracane C, Belluardo N, Giangreco E, Fries W, Viola A, Di Mitri R, Mocciaro F, Camilleri S, Garufi S, Renna S, Casà A, Maida M, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). Vedolizumab may be an effective option for the treatment of postoperative recurrence of Crohn's disease. Dig Liver Dis. 2022 May;54(5):629-634. IF: 4
37. Demarzo MG, Viola A, Picci A, Fries W. Letter: the clinical course of Crohn's disease-the Sicilian experience. Aliment Pharmacol Ther. 2022 May;55(9):1237-1238. IF: 8.1
38. Fries W, Demarzo MG, Navarra G, Viola A. Ulcerative Colitis in Adulthood and in Older Patients: Same Disease, Same Outcome, Same Risks? Drugs Aging. 2022 Jun 1:1–12. doi: 10.1007/s40266-022-00943-0. Epub ahead of print. IF: 3.9

1. M. Mendolaro, A. Viola, M.Cappello. Standard therapeutic approach and new therapies. In: G.Lo Re, M. Midiri (eds). Crohn’s disease. Radiological features and clinical-surgical correlations. Springer eBook 2015, Pages 59-74.

1. A. Viola, L. Cantoro, R. Monterubbianesi, F. Castiglione, M. Principi, I. Frankovic, D. Pugliese, F. Callela, S. Saibeni, A. Aratri, S. Orlando, M. Cappello, G. Costantino, N. Mannetti, G. Mocci, L. Samperi, G. Inserra, A.C. Privitera, F. Caprioli, V. Annese, C. Papi, A. Armuzzi, R. D'Incà, A. Kohn, F. Manguso, W. Fries. Crohn's disease (CD) in the elderly - an IG-IBD  study. J Crohns Colitis. 8:S293-S294. February 2014.
2. W. Fries, A. Viola, N. Mannetti, M. Coppola, I. Frankovic, R. Monterubbianesi, L. Cantoro, D. Pugliese, A. Aratri, M. Cappello, S. Saibeni, M. Principi, P. Naccarato, G. Mocci, F. Castiglione, F. Callela, A. Magarotto, F. Caprioli, A. Belvedere, G. Casella, L. Samperi, A.C. Privitera, G. Inserra, S. Danese, C. Papi, A. Armuzzi, A. Kohn, R. D'Incà, V. Annese, F. Manguso. Ulcerative colitis (UC) in the elderly – Moderate at onset but then a milder course? An IG-IBD study. J Crohns Colitis. 8:S190-S191 · February 2014.
3. M. Cintolo, A. Viola, M. Coppola, D. Pugliese, A. Ferrara, S. Saibeni, G. Mocci, F. Castiglione, F. Calella, F. Furfaro, C. Papi, V. Annese, F. Bossa, F. Manguso, W. Fries. Polypharmacy and adverse events to therapy in IBD patients – an analysis of the aged study (ig-ibd).   (Falk Symposium 192, IBD 2014: Thinking out of the box; Paris).
4. Fries W, Viola A, Monterubbianesi R, Manetti N, Frankovic I, Pugliese D, Aratari A, Cappello M, Coppola M, Cantoro L, Saibeni S, Principi M, Furfaro F, Fiorino G, Mocci G, Castiglione F, Scalisi G, Calella F, Magarotto A,  Caprioli F, Casella G, Samperi L, Inserra G, Antonino C. Privitera, Danese S, Ardizzone S, Papi C, Armuzzi A, Kohn A, Bossa F, D'Inca R, Annese V, Alibrandi A, Costantino G. Risk factor analysis for therapy related adverse events and infections in elder patients with inflammatory bowel disease; an analysis from the ig-ibd aged study. Gastroenterology , Volume 148 , Issue 4 , S-133. April 2015.
5. M. Mendolaro, M. Cappello, A. Viola, M.G. Cilluffo, G. Vita, S. Peralta, V. Calvaruso, A. Craxi. Hemoglobin and ferritin values are associated with increased rate of mucosal healing in patients with crohn's disease treated with anti-tnf alpha. Dig Liver Dis , Volume 48 , e158 - e159. February, 2016.
6. A. Viola, M. Cappello, M.G. Cilluffo, M. Mendolaro, A. Craxì, P.L. Almasio. A single infusion of ferric carboxymaltose effectively improves iron-deficiency anemia in patients with gastrointestinal and liver disease: a hospital-based survey. Dig Liver Dis., Volume 48 , e130. February 2016.
7. A. Viola M.Cappello, S.Petta, R.Filomia, M.Mendolaro, I.Cacciola, G.Squadrito, W.Fries. The Course of Inflammatory Bowel Disease in Patients Under Treatment with Direct Antiviral Agents for Hepatitis C – A preliminary Report. Dig Liver Dis. Vol 49, e163,2017. March, 2017
8. M. Scolaro, M.C. Naim, T. Pinto Vraca, G. Costantino, V. Pisana, A. Viola, A. Belvedere, S. Porcari, W. Fries. Changing the clinical course in ibd – steroid-free remission and surgery in two cohorts (≤2009 and >2009) – an interplay between disease pattern, biologics, and adherence. Dige Liver Dis. Vol 50 e136-e137, 2018.
9. D.Pugliese, F.Rogai A. Variola, A. Viola, A.C.Privitera, M. Allocca, F.Bossa, M.Cappello, G.Lorenzon, S.Mazzuoli, M.B.Principi, R.Sablich, A.Ferronato, S.Festa, L. Moser, G.Tapete, G.Bodini, M.Di Girolamo, L. Grossi, G. Mocci, F. Mocciaro, C. Ricci, S. Saibeni, R.Spagnuolo, C.C.Cortelezzi, B.Orlandini, E. Capoferro, G. Costantino, A .Armuzzi. Real-life study (gore-uc) evaluating the effectiveness of golimumab for the treatment of ulcerative colitis: an interim analysis from italian group for the study of inflamm bowel disease (ig-ibd). Dig Liver Dis. Vol 50 e136, 2018.
10. Centritto A, Sitibondo A, Squeri A, Viola A, Costantino G, Belvedere A, Pisana V, Costa G, Squeri R, Fries W. Vaccination strategies for IBD patients.  Falk Symposium 214 ''IBD: From Pathophysiology to Personalized Medicine'' Oxford, 29.03.-30.03.2019.
11. A. Viola, G. Fiocco, A. Alibrandi, F.S. Macaluso, M. Cappello, A.C. Privitera, G. Magrì, S. Garufi, A. Centritto, M. Ventimiglia, E. Giuffrida, C. Ferracane, G. Costantino, S. Renna, A. Orlando, W. Fries. Ustekinumab in Crohn’s disease: Real-world outcomes from the Sicilian Network for inflammatory bowel diseases (SN-IBD):–Preliminary results. J Crohns Colitis., Volume 14, Issue Supplement_1, Feb. 2020.
12. F.S. Macaluso, W. Fries, A. Viola, A. Centritto, M. Cappello, E. Giuffrida, A.C. Privitera, G. Piccillo, A. Magnano, E. Vinci, R. Vassallo, A. Trovatello, N. Belluardo, E. Giangreco, S. Camilleri, S. Garufi, C. Bertolami, M. Ventimiglia, S. Renna, R. Orlando, G. Rizzuto, M. Grova, A. Orlando. SPOSIB SB2: a Sicilian prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar SB2. J Crohns Colitis., Volume 14, Issue Supplement_1, Feb. 2020.
13. A. Sitibondo, A. Viola, G. Costantino, A. Centritto, A. Belvedere, V. Pisana, A. Abbruzzese, A. Alibrandi, W. Fries. Treatment strategies after mucosal healing (MH) in ulcerative colitis. J Crohns Colitis, Volume 14, Issue Supplement_1, Feb. 2020.
14. A. Viola, F. Giambò, M.F. Chiappetta, G. Costantino, S. Pallio, G. Navarra, A. Alibrandi, W. Fries. Management of patients with Inflammatory Bowel Disease and their outcome during the first wave of Covid-19 pandemics. J Crohns Colitis, Volume 15, Issue Supplement_1, May 2021.
15. R. Goll, J. Kay-Martin, A. Viola, E. Paulssen, Ø.K. Moe, G. Cui, W. Fries, J. Florholmen. TNF gene activation used as criterion to discontinue biologic therapy – A patient series introducing the NovaPrime TNF kit. J Crohns Colitis, Volume 15, Issue Supplement_1, May 2021.
16. F. Macaluso , M. Cappello , A. Busacca , W. Fries , A. Viola, G. Costantino, A. Magnano, E. Vinci, C. Ferracane, A.C. Privitera, G. Piccillo, N. Belluardo, E. Giangreco, C. Romano, M. Citrano, F. Graziano, S. Garufi, C. Bertolami, B. Scrivo, S. Renna, A. Casà, G. Rizzuto, M. Ventimiglia, A. Orlando, Sicilian Network for Infammatory Bowel Disease (SN-IBD). SPOSAB ABP 501 - A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501. J Crohns Colitis, Volume 15, Issue Supplement_1, May 2021.
17. M.F. Chiappetta, A. Viola, M. Mastronardi, L. Turchini, S. Carparellli, A. Orlando, G. Biscaglia, A. Miranda, L. Guida, G. Costantino, F. Scaldaferri, F. Bossa, S. Renna, M. Cappello, A. Orlando, A. Armuzzi, W. Fries. One year effectiveness and safety of ustekinumab in Ulcerative Colitis: a multicentre real-world study from Italy. J Crohns Colitis, Volume 15, Issue Supplement_1, May 2021.
18. F. Macaluso, W. Fries, S. Renna, A. Viola, M. Muscianisi, M. Cappello, L. Guida, S. Siringo, S. Camilleri, S. Garuf, A.C. Privitera, N. Belluardo, E. Giangreco, C. Bertolami, R. Vassallo, G. Rizzuto, R. Orlando, M. Ventimiglia, A. Orlando. Sicilian Network for Infammatory Bowel Diseases (SN-IBD).  Effectiveness and Safety of Vedolizumab in Biologic-Naïve Patients: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). J Crohns Colitis, Volume 15, Issue Supplement_1, May 2021.
19. F.S. Macaluso , M. Cappello, F. Crispino, M. Grova, A.C. Privitera, G. Piccillo, A. Magnano, C. Ferracane, N. Belluardo, E. Giangreco, W. Fries, A. Viola, R. Di Mitri, F. Mocciaro, S. Camilleri, S. Garuf, S. Renna, A. Casà, M. Maida, A. Orlando. Vedolizumab May Be An Effective Option For The Management Of Postoperative Recurrence Of Crohn’s Disease. Sicilian Network for Infammatory Bowel DIseases (SN-IBD). J Crohns Colitis, Volume 15, Issue Supplement_1, May 2021.
20. A. Viola, M.A. Barbieri, V. Pisana, P.M. Cutroneo, W. Fries, E. Spina. Effectiveness and safety profile of biological therapy in inflammatory bowel disease: real life data from an active pharmacovigilance project. J Crohns Colitis, Volume 15, Issue Supplement_1, May 2021.
21. Chiappetta MF, Viola A, Mastronardi M, Turchini L, Carparelli S, Orlando A, Biscaglia G, Miranda A,  Guida L, Costantino G, Scaldaferri F, Bossa F, Renna R, Cappello M, Orlando A, Armuzzi A, Fries W. One year effectiveness and safety of ustekinumab in refractory ulcerative colitis: amulticentre real-world study. Selezionato come Comunicazione orale al XII Congresso IG-IBD. Novembre 2021.
22. Viola A, Muscianisi M, Li Voti R, Costantino G, Abbruzzese A, Rao S, Ksissa O, Alibrandi A,  Fries W. Anti-covid-19 vaccination uptake in a cohort of ibd patients; a prospective study. Selezionato come Comunicazione orale al XII Congresso IG-IBD. Novembre 2021.

• XII Congresso Nazionale IGIBD, 28 novembre - 4 dicembre 2021 (online). Comunicazione orale: Anti-COVID-19 vaccination uptake in a cohort of IBD patients: a prospective study.
• Il rapport territorio-specialista nell’approccio corretto alle MICI. Milazzo 27 novembre 2021. Responsabile scientifico e relatrice: Il microbiota intestinale nelle MICI.
• Diagnosi e gestione delle malattie infiammatorie croniche dell'intestino (MICI)- Oltre il COVID-19 , Messina, 03 Luglio 2021. Relatrice: Immunosoppressori e terapie biologiche.
• Webinar “Casi clinici problematici: il punto di vista della SN-IBD nel management delle MICI in epoca di Covid-19”. 07 e 08 maggio 2021. Resposnabili scientifici: Dott. Fabio S. Macaluso, Dott. Ambrogio Orlando, Dott.ssa SaraRenna (Palermo). Relatrice: caso clinico “Pioderma gangrenoso resistente agli anti-TNF: cosa fare"
• Webinar "Gli errori più comuni nel management delle MICI in epoca COVID-19". 13-14 luglio 2021- Responsabili scientifici: Dott. Fabio S. Macaluso, Dott. Ambrogio Orlando(Palermo) Relatrice: caso clinico “Ma la chirurgia è l’ultima spiaggia?”
• Challenges in Transition care in inflammatory bowel diseases" - Giardini Naxos (ME) 8 e 9 novembre 2019. Relatrice: Risk of sexual dysfunctions in patients with IBD.
• La gestione del paziente anziano con malattia infiammatoria cronica dell'intestino -  Taormina (ME)  25 e 26 Ottobre 2019. Relatrice: CASO CLINICO: Diagnosi
• Evento – REOPEN, short bowel syndrome expert meeting. Palermo, 17/10/2019. Realtrice: 1° Caso Clinico Interattivo: un caso di sindrome da intestino corto secondario a malattia di Crohn plurioperata.
• VIII congresso trisocietario regionale siciliano AIGO-SIED-SIGE - Palermo il 2-3-4 maggio 2019. Relatrice: Gestione e opportunità dello “switch” con i biosimilari nelle IBD
• Reuma-Gastroenterologia...un universo in continua espansione - Messina 10 e 11 aprile 2018. Relatrice. Case report: paziente con switch multipli.
• La videocapsula endoscopica. Stato dell’arte. Caltanissetta, 13 aprile 2018. Relatrice: caso clinico
• 21° Congresso Nazionale delle Malattie Digestive. Bologna 25-28 Marzo 2015. Relatrice: risk factor analysis for therapy related adverse events and Infections in elder patients with inflammatory bowel disease; an Analysis from the ig-ibd aged study. Premio quale miglior contributo selezionato per la presentazione nella sessione Plenaria.
• VI CONGRESSO NAZIONALE IG-IBD Padova, 7-9 Novembre 2013. Relatrice:  An IG-IBD study: Ulcerative Colitis (UC) in the elderly – a preliminary analysis.

• NEW TREATMENTS IN IBD: EFFICACY, EFFECTIVENESS AND SAFETY FROM CLINICAL TRIALS TO REAL WORLD, Palermo, 10-11 giugno 2022
• 16 th Congress of ECCO Virtual – Inflammatory Bowel Diseases 2021. July 8-10, 2021
• XI Congresso Nazionale IG-IBD Webinar dal 29/11/2020 - 05/12/2020.
• 15th Congress of ECCO, Inflammatory Bowel Diseases 2020 Vienna, Austria, February 12-15, 2020
• X CONGRESSO NAZIONALE IG-IBD Riccione, 28-30 Novembre 2019
• Falk Symposium 214 ''IBD: From Pathophysiology to Personalized Medicine'' Oxford, 29.03.-30.03.2019
• Conference “Eosinophilic gastrointestinal diseases: new perspectives in diagnosis and management” UO di Gastroenterologia Pediatrica e Fibrosi Cistica. Messina, 05.07.2019.
• Ultra-sound nella malattia di Crohn – Roma 11-12 giugno 2018.
• Advanced Cardiovascular Life Support – ACLS. ISMETT, Palermo, 17-18 Maggio 2018.
• Falk Symposium 210: Crossing New Borders in IBD: Thoughts and Demands – From Mechanism ti Treatment. Lisbon, Portugal 20-21 April 2018.
• 13th Congress of ECCO, Inflammatory Bowel Diseases 2018 Vienna, Austria, February 14-17, 2018
• VIII CONGRESSO NAZIONALE IG-IBD Torino, 30 Novembre – 2 dicembre 2017
• Ultra-sound nella malattia di Crohn – Roma 6 novembre 2017, Napoli 14 novemre 2017.
• Corso teorico pratico sulle polipectomie endoscopiche – San Cataldo (CL) 3-4 novembre 2017, Messina 17-18 novembre 2017.
• Le Urgenze emorragiche in Endoscopia Digestiva: verso una gestione condivisa. Corso teorico-pratico. Messina 17-18 novembre 2017
• Focus sulle MICI – Palermo 12-13 maggio 2017
• MICI – Gestione multidisciplinare del paziente. Messina 13-14 gennaio 2017
• 12° Congress of Inflammatory Bowel Diseases - ECCO | Barcellona | 15-18 Febbraio 2017
• IG-IBD “Evidence Based Medicine (EBM) in Inflammatory Bowel Disease” – Corso residenziale avanzato, Lido di Camaiore 12-13 novembre 2016
• L’epatocarcinoma nel 2016: nuovi approcci per la diagnosi ed il trattamento. Ospedale Cervello (PA) 2 maggio 2016
• 22° Congresso Nazionale delle Malattie Digestive (FISMAD). Napoli 24-27 febbraio 2016 
• 11 th Congresso of ECCO, Inflammatory Bowel Disease 2016 Amsterdam, 16-19 marzo 2016
• VII CONGRESSO NAZIONALE IG-IBD Palermo, 3-5 dicembre 2015
• Sliding doors: corso teorico pratico sulle malattie infiammatorie croniche intestinali. Roma – 20 novembre 2015.
• Live advanced in Endoscopy. Palermo 9 ottobre 2015
• BOOST in UC. Lamezia Terme 25-26 settembre 2015
• WEF incontra EXPO. Primo workshop di economia e farmaci per la celiachia e altri disturbi glutine-correlati. Milano 8-9 giugno 2015
• Fifth Mediterranean Congress: Innovative Scenario in Internal Medicine. Palermo 29-30 maggio 2015
• Malattie Infiammatorie Croniche dell’Intestino – Integrazione assistenziale. Palermo 11 aprile 2015
• Nuovi algoritmi terapeutici nelle IBD. Palermo, 13-14 marzo 2015
• La terapia farmacologica delle Malattie Infiammatorie Immuno-Mediate: dai trattamenti Convenzionali ai Farmaci Biotecnologici. Bologna 5-7 Marzo 2015.
• Safety of immunosuppressive treatment in the management of Inflammatory Bowel Disease, Palermo 13 Dicembre 2014 
• International Falk Symposium n. 192, IBD 2014: Thinking out of the box; 30-    31 May 2014, Paris, France. Third poser prize.
• Patologie infiammatorie intestinali: gestione clinica ed appropriatezza terapeutica. Giardini Naxos (ME) 27 novembre 2014. 
• Stipsi. Una corretta diagnosi, un giusto trattamento” Messina 20 Settembre 2014
• BLS-D Basic Life Support- Defibrillation. 06 maggio 2014, Ordine dei Medici di Reggio Calabria.
• VI CONGRESSO NAZIONALE IG-IBD Padova, 7-9 Novembre 2013. 
• 1° Focus on “Carcinoma pancreatico: gestione multidisciplinare”. Messina 7 giugno 2013
• Workshop Hepatology Perspectives. Reggio Calabria 6 giugno 2012
• “Alla scoperta delle malattie infiammatorie croniche intestinali: dal bambino all’adulto”, Giardini Naxos, Messina, 3 marzo 2012

• European Journal of Gastroenterology & Hepatology
• Scientific Reports
• International Journal of Clinical Practice

• IG-IBD - Italian Group for the study of Inflammatory Bowel Disease
• ECCO - European Crohn´s and Colitis Organisation
• SIED - Società Italiana Endoscopia Digestiva

• Frontiers in Oncology, in Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers (Review Editor)

• Terzo premio come miglior abstract al Falk Symposium n. 192, IBD 2014: Thinking out of the box; 30-    31 May 2014, Paris, France. “Crohn's disease (CD) in the elderly – the aged- study on behalf of IG-IBD”.   
• Premio quale miglior contributo selezionato per la presentazione nella sessione Plenaria al 21° Congresso Nazionale delle Malattie Digestive. Bologna 25-28 Marzo 2015. “Risk factor analysis for therapy related adverse events and Infections in elder patients with inflammatory bowel disease; an Analysis from the IG-IBD aged study”.

• Capacità di lettura: ottimo
• Capacità di scrittura: buono
• Capacità di espressione orale: buono

Curriculum

CURRICULUM VITAE
 
PERSONAL INFORMATION
First name: Anna
Surname: Viola
Adress: Via Salita Stazione Santa Caterina n.21
Telephone: ++3338377928
Place and Date of birth: Genova 06/05/1988
 
ACTUAL POSITION 
Researcher in Gastroenterology (RTDA SSD MED/09)
University of Messina. Dept. of Clinical and Experimental Medicine
 
WORK ADDRESS
Dipartimento di Medicina Clinica e Sperimentale,
Policlinico Universitario “G. Martino”,
via C. Valeria, 98121 Messina
Tel. +39-090-2212387
Fax: +39-090-2212387
email: aviola@unime.it
 
 
EDUCATION AND TRAINING.
 
Medical boards with marks 180/180 and registration with the Register of Doctors of Reggio Calabria
Faculty of Medicine and Surgery, Univeristy of Messina
February 2014
 
Medical Doctor degree in Medicine and Surgery
University of Messina, Italy
Final mark: 110/110 (cum laude)
July 2013
 
 
Secondary School Diploma in Scientific Studies
Liceo scientifico “A. Volta”, Reggio Calabria, Italy
Final mark: 100/100 (cum laude)
July 2007
 
 
WORK EXPERIENCE.
Researcher in Gastroenterology (RTDA SSD MED/09)
University of Messina. Dept. of Clinical and Experimental Medicine
December 2021 - Present
 
PhD student in Medical and Surgical Biotechnology
Director prof. G. Squadrito, Tutor prof. W. Fries
February 2019 – Present
Subinvestigator in clinical trials
U.O.S.D of Inflammatory Bowel Disease, Policlinico of Messina
Director Prof. Walter Fries
February 2020 - Present
 
Specialist in “Malattie dell’Apparato Digerente”
University of Palermo, Italy. Final marks: 50/50 cum laude
May 2019
 
Resident in U.O.S.D of Digestive Endoscopy, Policlinico of Messina
Director prof. S. Pallio
September 2017 – September 2018
 
Resident in U.O.S.D of Inflammatory Bowel Disease, Policlinico of Messina
Director prof. W. Fries
September 2016 – September 2017
 
Resident in Gastroenterology and Hepatology, Policlinico of Palermo
Director prof. C. Cammà
December 2014 –September 2016
 
 
Continual Assistance Service, Medical Assistance of Roccella Jonica (RC)
ASP of Reggio Calabria
April 2014 – May 2014
 
TEACHING ACTIVITY
Subject Expert in “Psiche e Apparato Digerente” – CdL Magistrale in Psicologia Clinica e della Salute nel Ciclo della Vita (SSD MED/09)
Dept. of Clinical and Experimental Medicine
October 2021 – September 2024
 
Subject Expert in “Patologia dell’Apparato Digerente” - CdL in Scienze Nutraceutiche ed Alimenti Funzionali.
Dept. of Clinical and Experimental Medicine
October 2021 – September 2024
 
REFEREE FOR JOURNALS
• European Journal of Gastroenterology & Hepatology
• Scientific Reports
• International Journal of Clinical Practice
 
EDITORIAL BOARD MEMBER
• Frontiers in Oncology, in Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers (Review Editor)
MEMBER OF SCIENTIFIC SOCIETY
• IG-IBD - Italian Group for the study of Inflammatory Bowel Disease
• ECCO - European Crohn´s and Colitis Organisation
• SIED - Società Italiana Endoscopia Digestiva
 
RECOGNITIONS AND AWARDS
• Third poser prize at the International Falk Symposium n. 192, IBD 2014: Thinking out of the box; 30-    31 May 2014, Paris, France
• Best oral comunication at 21° Congresso Nazionale delle Malattie Digestive. Bologna 25-28 Marzo 2015. “Risk factor analysis for therapy related adverse events and Infections in elder patients with inflammatory bowel disease; an Analysis from the IG-IBD aged study”.